Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Volume 25, Number 9—September 2019

Research

Effect of Pneumococcal Conjugate Vaccines on Pneumococcal Meningitis, England and Wales, July 1, 2000–June 30, 2016

Godwin Oligbu, Sarah Collins, Abdelmajid Djennad, Carmen L. Sheppard, Norman K. Fry, Nick J. Andrews, Ray Borrow, Mary E. Ramsay, and Shamez N. LadhaniComments to Author 
Author affiliations: Public Health England, London, UK (G. Oligbu, S. Collins, A. Djennad, C.L. Sheppard, N.K. Fry, N.J. Andrews, M.E. Ramsay, S.N. Ladhani); St. George's, University of London, London (G. Oligbu, S.N. Ladhani); Public Health England Manchester Royal Infirmary, Manchester, UK (R. Borrow)

Main Article

Figure 5

Pneumococcal meningitis cases, by Streptococcus pneumoniae serotype and severity, England and Wales, July 1, 2015–June 30, 2016. We included the non-PCV13 serotypes that involved >10 cases. PCV7, 7-valent pneumococcal conjugate vaccine; PCV13, 13-valent pneumococcal conjugate vaccine.

Figure 5. Pneumococcal meningitis cases, by Streptococcus pneumoniae serotype and severity, England and Wales, July 1, 2015–June 30, 2016. We included the non-PCV13 serotypes that involved >10 cases. O, other serotypes; PCV7, 7-valent pneumococcal conjugate vaccine; PCV13, 13-valent pneumococcal conjugate vaccine.

Main Article

Page created: August 20, 2019
Page updated: August 20, 2019
Page reviewed: August 20, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external